Advaxis Announces Positive Clinical Data in Ongoing Phase 1/2 ADXS-503 Trial in NSCLC at the IASLC 2020 Targeted Therapies of Lung Cancer Meeting
Stock Information for Advaxis Inc.
Loading
Please wait while we load your information from QuoteMedia.